About Ab Initio
Ab Initio is a company based in San Francisco (United States) founded in 2015 was acquired by Ligand Pharmaceuticals in July 2019. Ab Initio offers products and services including OmniRat, OmniMouse, OmniChicken, and Omni dAb. Ab Initio operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omniab, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Ligand Pharmaceuticals
(Jul 23, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ab Initio
Ab Initio offers a comprehensive portfolio of products and services, including OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Transgenic rat platform for producing human antibodies.
Transgenic mouse system for antibody discovery research.
Transgenic chicken host for diverse antibody repertoires.
Platform for single-domain antibody generation and applications.
Funding Insights of Ab Initio
Detailed funding history for Ab Initio
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Ab Initio
Ab Initio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Locked | Locked | Locked |
Investor details for Ab Initio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ab Initio
Investment portfolio details for Ab Initio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ab Initio
Detailed financials for Ab Initio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ab Initio Comparisons
Peer comparison for Ab Initio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ab Initio
Ab Initio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Ab Initio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ab Initio
Complete news archive for Ab Initio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ab Initio
Ab Initio was founded in 2015.
Ab Initio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ab Initio was founded in 2015 in San Francisco, United States, within the biotechnology sector. A directed evolution display-based platform is utilized alongside protein receptor biochemistry techniques for discovering therapeutics. Focus is placed on antibodies that activate or inactivate G-protein coupled receptors, as well as multispecific agents for cancer immunotherapy engaging innate and adaptive immune responses. A collaboration with Pfizer was announced in December 2016 for GPCR antibody development.
Ab Initio's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Ab Initio offers OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Ab Initio has 1 investor. Key investors include Ligand Pharmaceuticals.